Researchers from the Max Planck Institute for Experimental Medicine in Göttingen and Ludwig Maximilian University in Munich have decoupled the production of growth factor IGF2 from the sleep-wake rhythm and found that it improved long-term memory in mice. This could also have been due to a disturbed sleep-wake rhythm. However, older mice exhibited abnormal behavior. High levels of IGF2 and a permanently disrupted sleep rhythm evidently damage the brain over the long term. This finding is medically significant because IGF2 is a candidate substance for improving memory impairment in Alzheimer patients.
Much of what we learn during the day is stored temporarily in the hippocampus. Later, during the transition from the waking to the sleep phase, the memories are consolidated. During sleep, memory traces are transferred to other brain regions for permanent storage. Sleep therefore plays a key role in how memories are moved from short-term to long-term memory.
Scientists have identified several mechanisms that control memory formation and regulate sleep-wake cycles, but they still do not know how the two processes interact at the molecular level. “We wanted to find out how sleep-wake regulation affects memory consolidation,” says Ali Shahmoradi from the Max Planck Institute of Experimental Medicine, in a release. The research group tracked down the effect of a specific molecule: insulin-like growth factor 2 (IGF2). Moritz Rossner, who led the study at the Max Planck Institute in Göttingen, says, “The polypeptide evidently accelerates the consolidation of declarative memory, which is memory that can be consciously recalled. Mice with high IGF2 levels in the cerebral cortex learn faster.”
The researchers studied genetically modified mice in which the sleep-wake rhythm was disturbed and normal circadian regulation of IGF2 in the cerebral cortex was switched off. This means that growth factor IGF2 and its effects were no longer linked to the sleep-wake rhythm. Moreover, production of the polypeptide was greatly increased. The mice therefore not only had a better memory than normal mice, but were also mentally fitter. However, they often had to take a nap during the activity phase in order to regenerate.
Neuroscientists believe that IGF2 improves mental performance, and it is a candidate substance for treating Alzheimer patients. The Max Planck researchers discovered in their study, however, that IGF2 causes long-term damage to the brain. The mice not only exhibited improved long-term memory but also abnormal behavior patterns. For example, they were more nervous and anxious. And the enhanced memory performance itself proved short-lived. It declined drastically in older mice. Rossner therefore cautions: “The use of IGF2 in the treatment of Alzheimer’s disease needs to be critically examined. Our study suggests that a persistently high concentration of the substance can harm the brain.”